Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 20;13(1):6.
doi: 10.1007/s12672-022-00468-3.

Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors

Soojung Hong  1   2 , Benjamin Daniels  3 , Marina T van Leeuwen  3 , Sallie-Anne Pearson #  3 , Claire M Vajdic #  3
Affiliations

Incidence and risk factors of hypertension therapy in Australian cancer patients treated with vascular signalling pathway inhibitors

Soojung Hong et al. Discov Oncol. .

Abstract

Background: Clinical trials report systemic hypertension is an adverse effect of vascular signalling pathway inhibitor (VSPi) use. There are limited data from routine clinical practice. We aimed to estimate the real-world incidence and risk factors of new-onset and aggravated hypertension for cancer patients dispensed VSPi in whole-of-population Australian setting.

Methods: We used dispensing records for a 10% random sample of Australians to identify treatment with subsidised VSPi from 2013 to 2018. We further identified dispensings of oral antihypertensive medicines 6 months before and 12 months after VSPi therapy. We defined (i) new-onset hypertension in people first dispensed antihypertensives after VSPi and (ii) aggravated hypertension in people with prior antihypertensive use dispensed an additional, or higher strength, antihypertensive after VSPi. We applied the Fine-Gray cumulative incidence function and Cox proportional hazard regression.

Results: 1802 patients were dispensed at least one VSPi. The mean age of the cohort was 65 years and 57% were male. The incidence of new-onset treated hypertension was 24.3% (95%CI: 21.2-27.8); age ≥ 60 years (HR 1.74; 95%CI: 1.32-2.31) and treatment with oral tyrosine kinase inhibitors compared to bevacizumab (HR 1.96; 95%CI: 1.16-3.31) were risk factors. The incidence of aggravated hypertension was 25.2% (95%CI: 22.0-28.7) and risk was elevated for patients with renal cancer (HR 2.84; 95%CI: 1.49-5.41) and cancers other than colorectal (HR 1.85; 95%CI: 1.12-3.03).

Conclusions: Our real-world estimates of incident hypertension appear comparable to those observed in clinical trials (21.6-23.6%). Our population-based study provides some insight into the burden of hypertension in patients commencing VSPi in routine practice.

Keywords: Cancer; Hypertension; Incidence; Risk factors; Vascular signalling pathway inhibitors.

PubMed Disclaimer

Conflict of interest statement

Sallie-Anne Pearson is a member of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee. The views expressed in this paper do not represent those of either Committee. The Centre for Big Data Research in Health, UNSW Sydney has received funding from AbbVie Australia to conduct research unrelated to the present study. AbbVie did not have any knowledge of, or involvement in, the present study. The remaining authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Consort flow diagram of study population
Fig. 2
Fig. 2
Cumulative incidence of hypertension therapy in Australians dispensed VSPi
See this image and copyright information in PMC

References

    1. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–27. doi: 10.1200/jco.2005.06.081. - DOI - PubMed
    1. Dreyfus B, Kawabata H, Gomez A. Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors. Cancer Epidemiol. 2013;37:191–196. doi: 10.1016/j.canep.2012.11.001. - DOI - PubMed
    1. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388:518–529. doi: 10.1016/s0140-6736(15)01088-0. - DOI - PubMed
    1. Mouhayar E, Durand J-B, Cortes J. Cardiovascular toxicity of tyrosine kinase inhibitors. Expert Opin Drug Saf. 2013;12:687–696. doi: 10.1517/14740338.2013.788642. - DOI - PubMed
    1. Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. doi: 10.1038/s41698-018-0056-z. - DOI - PMC - PubMed

LinkOut - more resources